Intensity-Modulated Radiation Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

UNC Lineberger awarded $11.9M grant to study radiation treatments for prostate cancer
(UNC Lineberger Comprehensive Cancer Center) The Patient-Centered Outcomes Research Institute has awarded UNC Lineberger Comprehensive Cancer Center's Ronald C. Chen, MD, MPH, a five-year, nearly $12 million grant to fund a comparative study of intensity-modulated radiation therapy and proton beam for prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 18, 2017 Category: Cancer & Oncology Source Type: news

UNC Lineberger awarded $11.9 million grant to study radiation treatments for prostate cancer
(UNC Lineberger Comprehensive Cancer Center) The Patient-Centered Outcomes Research Institute has awarded UNC Lineberger Comprehensive Cancer Center's Ronald C. Chen, MD, MPH, a five-year, nearly $12 million grant to fund a comparative study of intensity-modulated radiation therapy and proton beam for prostate cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2017 Category: International Medicine & Public Health Source Type: news

Varian Medical wins Brazilian regulatory nod for Halcyon system
Varian Medical (NYSE:VAR) said today it won Brazilian ANVISA clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring nine steps from start to treatment, down from 30 steps in legacy machines. Varian Medical said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck and other forms of cancer. “Halcyo...
Source: Mass Device - December 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

Varian Halcyon Treatment System Receives ANVISA Registration in Brazil
New advanced cancer treatment system from Varian now available to cancer centers in Brazil PALO ALTO, Calif., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Further expanding the global availability of its new device for cancer treatment, Va... Devices, Oncology, Regulatory Varian Medical Systems, Halcyon System, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news

Varian Medical wins Japanese nod for Halcyon oncology radiotherapy system
Varian Medical (NYSE:VAR) said today it won Shonin approval from the Japanese Ministry of Health, Labor and Welfare for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. Varian Medical said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck...
Source: Mass Device - November 16, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

Proton therapy for prostate cancer is advantageous to imrt according to new study
(Northwestern Memorial HealthCare) Proton therapy treatment for prostate cancer is associated with higher survival rates and decreased risk of complications compared to intensity-modulated radiation therapy (IMRT) according to a new study by researchers at the Northwestern Medicine Chicago Proton Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 25, 2017 Category: International Medicine & Public Health Source Type: news

Varian launches Halcyon treatment in EU
Varian Medical (NYSE:VAR) said today it launched its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system in the European Union, with the 1st patient being treated in Blegium. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. Varian said the device is designed to handle “the majority” of cancer patients, including individuals with prostate, breast, head & neck and other ...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Oncology Varian Medical Systems Source Type: news

European Court of Appeal Rejects Varian's Attempt to Reverse Customer Purchase of Accuray TomoTherapy(R) System
SUNNYVALE, Calif., Oct. 19, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accur... Devices, Oncology, Litigation Accuray, Varian Medical Systems, TomoTherapy, radiotherapy, IMRT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 19, 2017 Category: Pharmaceuticals Source Type: news

High-precision radiotherapy for prostate cancer 'shows promise'
Conclusion This study shows some promising results for targeted pelvic lymph node radiotherapy for men with advanced localised prostate cancer. However, these results can only be treated as preliminary findings for now. This was an early-stage trial that aimed to investigate whether the treatment approach is safe and to get an idea of what doses may be suitable for assessment in further trials. Although it can give an indication of effectiveness, this was not the main aim of the study. Men were not randomised to a treatment group, which means there may have been some differences in the cancers or patient characteristics of...
Source: NHS News Feed - September 26, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

ASTRO: Short radiation course safe for breast cancer
A shorter-course, higher-dose protocol for breast cancer radiation therapy...Read more on AuntMinnie.comRelated Reading: LED device could predict skin damage from breast RT Breast cancer radiation boosts heart disease risk NEJM: RT boosts heart disease risk in breast cancer patients Robotic IMRT-APBI works well for breast cancer patients ASTRO publishes guidelines for accelerated whole-breast RT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 26, 2017 Category: Radiology Source Type: news

Varian Announces Penn Medicine Treats World's First Patient on Halcyon System
PALO ALTO, Calif., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced a patient at Penn Medicine, with head & neck cancer, became the first person in the world to be treated on Varian's Halcyon ... Devices, Oncology Varian Medical Systems, Halcyon System, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Accuray wins FDA nod for iDMS data management system
Accuray (NSDQ:ARAY) said today it won FDA 510(k) clearance for its iDMS data management system designed for sharing data between the company’s treatment delivery platforms. The Sunnyvale, Calif.-based company said the iDMS system is designed to integrate data from its technology platforms, including the Radixact, TomoTherapy and CyberKnife systems, as well as the company’s Accuray Precision treatment planning and oncology information systems. The iDMS allows users to store and manage all patient and treatment data across multiple devices to allow for more informed, efficient radiation treatments, Accuray sai...
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Software / IT Accuray Inc. Source Type: news

Accuray touts study data in head-to-head between TomoTherapy and Varian ’ s RapidArc
Accuray (NSDQ:ARAY) today released data from a prospective study comparing its TomoTherapy intensity-modulated radiation therapy system with Varian Medical‘s (NYSE:VAR), RapidArc radiotherapy system, touting a higher survival rate for patients treated with its TomoTherapy system. Results from the study were published last month in the International Journal of Radiation Oncology – Biology – Physics. Accuray said that the 166-patient, multi-center study was the 1st to prospectively compare clinical outcomes across radiation platforms. In the study, 74 individuals were treated with the TomoTherapy system ...
Source: Mass Device - July 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology Accuray Inc. Varian Medical Systems Source Type: news

Varian Medical wins FDA nod for Halcyon radiotherapy cancer treatment system
Varian Medical (NYSE:VAR) said today it won FDA 510(k) clearance for its Halcyon image-guided volumetric intensity modulated radiotherapy cancer treatment system. The Palo Alto, Calif.-based company said its Halcyon IMRT system features improvements that make it more comfortable for patients and streamline operator’s workflow, only requiring 9 steps from start to treatment, down from 30 steps in legacy machines. “We are proud that Halcyon has now received both 510(k) clearance and CE mark. With its human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow. These two clea...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Varian Medical Systems Source Type: news

IUCT Oncopole Advances Cancer Care in France with the New Accuray Radixact(TM) System
The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray SUNNYVALE, Calif., June 20, 2017 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (NASDAQ: AR... Devices, Oncology Accuray, Radixact, Delivery System, IGRT, IMRT, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 20, 2017 Category: Pharmaceuticals Source Type: news